- Home
- GIGM vs TPST Comparison
GIGM vs TPST Comparison
Compare GIGM & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | TPST |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.1M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | TPST |
|---|---|---|
| Price | $1.54 | $2.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.1K | ★ 84.3K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $2.35 |
| 52 Week High | $1.89 | $12.48 |
Technical Indicators
Market Signals| Indicator | GIGM | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 31.74 |
| Support Level | $1.46 | $2.55 |
| Resistance Level | $1.59 | $3.00 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 62.79 | 11.24 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.